Market Scope

Market Research Future (MRFR) assessed the global influenza vaccines market 2020 through the review period till 2030. As per MRFR study, the influenza vaccine market is expected to register 6.53% CAGR through the study period. By 2030, the influenza vaccine market size is likely to touch USD 11.7 Bn by 2030. The COVID 19 pandemic is expected to contribute significantly to the upsurge of the influenza vaccine market owing the the panic induced by the contagion SARS-CoV-2 and its mutating strains. The surge in demand for vaccination to restore and enhance public health from infectious virus can favor the global influenza vaccines market in the foreseeable future. Moreover, the growing cases of avian flue can contribute to the increasing sales influenza vaccines that can benefit the market.

Market Drivers and Restrains

The infection of the upper respiratory airway induced by an influenza virus is commonly called as flu, characterized by high fever, coughing, headache, sore throat, and sneezing. The increase in number of people diagnosed with different strain of influenza is creating the need for effective diagnosed to deliver best treatment regimen. Recently, influenza epidemics are also recorded across several regions. Thus, the increasing awareness about such infections have resulted in the launching of effective measures by both government and global healthcare leaders to boost community health. The increase in  funding for research and development undertaking to boost preparedness for epidemic and introduce product that can offer better influenza management can add to the market impetus.

Key Influenza Vaccination Market Players

Abbott (U.S.), AstraZeneca (Europe), Novartis AG (Europe),  BioCryst Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline plc. (Europe). DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), Hualan Biological Engineering Inc (Asia Pacific),  F. Hoffmann-La Roche Ltd (Europe), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), Paxvax Corporation (U.S.), and Sanofi (Europe) are some top-notch companies that are enlisted by MRFR to gain insights into the global influenza vaccination market.

Segment Assessment of Global Influenza Vaccination Market

The segment assessment of the global influenza vaccines market outlook is based on influenza Type, End User, Manufacturing Technology, and Vaccine Type.

The influenza type-based segments of the global influenza market are zoonotic and seasonal. The seasonal segment can rise at high pace owing to the rise in epidemic in certain region over a period of time in a year.

The manufacturing technology-based segments of the influenza market are egg-based, recombinant-based, and cell culture-based. The recombinant-based segment can acquire high revenue from the market owing to the introduction of several innovation by reputed biotechnology companies focusing on improve health and quality of life of people. The cell-culture based manufacturing technology can be gain traction.

The vaccine type-based segments of the global influenza vaccines market are quadrivalent vaccines and trivalent vaccines. The trivalent vaccines segment is expected to thrive due to its convenience.

The end user-based segments of the global influenza vaccines market are hospitals and clinics, academic institutions, and research organizations among others. The academic institution segment can benefit the global influenza vaccines market, following the hospitals and clinics segment.

Regional Analysis of Global Influenza Vaccination Market

North America is expected to head the global influenza vaccination market in terms of market size. The high prevalence of influenza and hike in per capita healthcare expenditure can drive North America influenza vaccination market in the near future. The existence of well-developed economies, such as Canada and the U.S. can garner decent revenue for the influenza vaccination market in the near future. The expansion of the ageing population and their high susceptibility to infectious ailments are causes contributing to the increasing demand for influenza vaccine that can prompt the growth of the influenza vaccination market.

In Europe, the influenza vaccination market can garner decent profit owing to the easy availability of funds for research to develop effective solutions to the increasing number of flu epidemics. Companies, such as Novartis AG and F. Hoffmann-La Roche Ltd, are influence EU influenza vaccination market.

In Asia Pacific, the influenza vaccination market can acquire high revenue for the global market in the assessment tenure. India and Japan are introducing favourable government healthcare policies for the expanding geriatric population that can promote the market surge.

In The Middle East and Africa region, the influenza vaccination market is expected to experience a sluggish growth. This is due to the several socioeconomic constrains. Latin America influenza vaccination market can witness passive surge due to the gradual development of the medical and technical setup in the region.